Product Description
Mechanisms of Action: CRTH2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Asthma|Rhinitis, Allergic, Seasonal|Rhinitis, Allergic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2009-017267-41 | P2 |
Completed |
Asthma |
2010-09-02 |
|
CQAV680A2201E1 | P2 |
Terminated |
Asthma |
2010-09-01 |
32% |
CQAV680A2204 | P2 |
Completed |
Rhinitis, Allergic |
2010-07-28 |
|
2008-005168-15 | P2 |
Completed |
Asthma |
2009-10-07 |